A share price of Avidity Biosciences Inc [RNA] is currently trading at $29.55, up 3.47%. An important factor to consider is whether the stock is rising or falling in short-term value. The RNA shares have lost -0.34% over the last week, with a monthly amount drifted -7.54%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $72. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on November 26, 2024, and set its price target to $67. On September 24, 2024, Goldman initiated with a Buy rating and assigned a price target of $59 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $63 on August 28, 2024. BofA Securities initiated its recommendation with a Buy and recommended $40 as its price target on May 03, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on March 14, 2024, and assigned it a price target of $60. In a note dated May 22, 2023, Evercore ISI upgraded an Outperform rating on this stock but restated the target price of $20.
Avidity Biosciences Inc experienced fluctuations in its stock price throughout the past year between $18.56 and $56.00. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $29.55 at the most recent close of the market. An investor can expect a potential return of 99.66% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Trailing Twelve Months sales for Avidity Biosciences Inc [NASDAQ:RNA] were 10.90M which represents 35.57% growth. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -34.77%, Pretax Profit Margin comes in at -29.58%, and Net Profit Margin reading is -29.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.26 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.71 points at the first support level, and at 27.86 for the second support level. However, for the 1st resistance point, the stock is sitting at 30.36, and for the 2nd resistance point, it is at 31.16.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avidity Biosciences Inc [NASDAQ:RNA] is 15.73. On the other hand, the Quick Ratio is 15.73, and the Cash Ratio is 2.24. Considering the valuation of this stock, the price to sales ratio is 325.90, the price to book ratio is 2.49.
Transactions by insiders
Recent insider trading involved Gallagher Kathleen P., Chief Program Officer, that happened on Mar 03 ’25 when 5875.0 shares were sold. Chief Program Officer, Gallagher Kathleen P. completed a deal on Feb 03 ’25 to sell 5875.0 shares. Meanwhile, Officer KATHLEEN GALLAGHER bought 17625.0 shares on Feb 03 ’25.
